A pivotal BMC Cancer study introduces a platform using circulating tumor DNA (ctDNA) to personalize adjuvant chemotherapy in colon cancer patients by detecting minimal residual disease. This advance marks a significant stride toward precision oncology, offering tailored postoperative treatment intensification to improve outcomes in colorectal cancer management.